What is it about?
To test the hypothesis that polymorphism within the gene-linked polymorphic region (5-HTTLPR) and second intron of SLC6A4 gene (STin2) is associated with selective serotonin-reuptake inhibitors (SSRIs) response in subjects with premature ejaculation (PE).
Featured Image
Photo by David Clode on Unsplash
Why is it important?
Premature ejaculation (PE) is the most prevalent male sexual dysfunction. The prevalence of PE varies widely among societies. From primary-care settings the reported prevalence of PE is 31% in the USA and 66% in Germany. The current most popular pharmacotherapeutic approach to treat PE is ‘off-label’ administration of selective serotonin (5-hydroxytryptamine, 5-HT)-reuptake inhibitors (SSRIs, e.g. paroxetine, fluoxetine, sertraline, citalopram, and escitalopram), which are reported to be effective for treating PE.
Perspectives
The present findings suggest the possibility of a genetic influence on individual differences in the response to SSRI treatment for patients with PE. Pharmacogenetics appears to be the future hope of pharmacotherapy for PE. Further studies are required to clarify the complex interactions that might involve 5-HTTLPR, the functioning of brain regions, and PE.
Dr Mohammad Reza Safarinejad
University of Medical Sceices
Read the Original
This page is a summary of: Analysis of association between the 5-HTTLPR and STin2 polymorphisms in the serotonin-transporter gene and clinical response to a selective serotonin reuptake inhibitor (sertraline) in patients with premature ejaculation, BJU International, January 2010, Wiley,
DOI: 10.1111/j.1464-410x.2009.08714.x.
You can read the full text:
Resources
Contributors
The following have contributed to this page
